BAY 3018250
Alternative Names: Anti-a2AP; BAY-3018250Latest Information Update: 04 Oct 2024
Price :
$50 *
At a glance
- Originator Bayer
- Class Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Antiplasmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Thrombosis
- Phase I Pulmonary embolism; Stroke; Vascular disorders
Most Recent Events
- 04 Oct 2024 Bayer plans a phase I trial Thrombosis (in volunteers) in China (Parenteral) (NCT06619483)
- 18 Sep 2024 Phase-I clinical trials in Vascular disorders (In volunteers) in USA (IV, infusion) (NCT06562985)
- 18 Sep 2024 Phase-I clinical trials in Vascular disorders (In volunteers) in USA (IV, injection) (NCT06562985)